Last reviewed · How we verify

Filgrastim (G-CSF) — Competitive Intelligence Brief

Filgrastim (G-CSF) (Filgrastim (G-CSF)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Granulocyte-colony stimulating factor (G-CSF). Area: Oncology, Immunology, Hematology.

phase 3 Granulocyte-colony stimulating factor (G-CSF) G-CSF receptor (GCSFR) Oncology, Immunology, Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Filgrastim (G-CSF) (Filgrastim (G-CSF)) — University of Miami. Filgrastim is a granulocyte-colony stimulating factor (G-CSF) that stimulates the bone marrow to produce and release neutrophils into the bloodstream.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Filgrastim (G-CSF) TARGET Filgrastim (G-CSF) University of Miami phase 3 Granulocyte-colony stimulating factor (G-CSF) G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Granulocyte-colony stimulating factor (G-CSF) class)

  1. University of Miami · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Filgrastim (G-CSF) — Competitive Intelligence Brief. https://druglandscape.com/ci/filgrastim-g-csf. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: